Fitabeo Therapeutics, a clinical stage biotech that develops and commercialises innovative medicine, today announced its partnership with Pharmanovia, a global pharmaceutical company that revitalises, extends and expands the lifecycle of established medicines.
The collaboration will seek to make the administration of two of its established medicines more convenient, ultimately improving adherence and anticipated patient outcomes, using Fitabeo Therapeutics’ proprietary drug delivery technology.
The technology allows products to be delivered simply, by applying a thin medicinal film to the inside of the mouth.
Mallikarjun Chityala, CEO of Fitabeo Therapeutics said “Our relationship with Pharmanovia is significant to our journey and is a testament to evolving strategies of delivering medicines via oral thin films and our innovative technologies to deliver Patient-Centric medicines to provide superior health outcomes.”
Pharmanovia CEO, James Burt commented; “Pharmanovia and Fitabeo Therapeutics are aligned in our ambitions to find new and innovative ways to enhance and revitalise iconic medicines. Together we seek to reduce the drug administrative burden among those in need, by providing innovative solutions to improve the patient experience, which in turn may lead to greater medication adherence.”
For further information, please contact:
Mallikarjun Chityala, CEO, Fitabeo Therapeutics
Alison Dyson, Director of Communications, Pharmanovia
About Fitabeo Therapeutics
Fitabeo Therapeutics is a clinical-stage specialty pharmaceutical company develops and commercialises innovative medicines focusing on indications where existing treatments are inadequate for the target population to provide better health outcomes. It deploys groundbreaking technologies to develop medicines that are expected to enable decentralised patient care and provide significant healthcare savings.
Pharmanovia is a global lifecycle management healthcare company. Our mission is to revitalise iconic medicines for the benefit of patients, prescribers and payors, and utilise our capabilities to launch novel therapies.
With a diverse and growing team in over 140 countries across the globe, we deliver high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Oncology, Endocrinology, Neurology and Cardiovascular